Edgar G Celis, MD
Pain Management · San Rafael
- Medicare standing
- Clear
- Enrolled, allowed to bill and order, not excluded
- Plans that list them
- 12
- 2 carriers
- Offices
- 2
- Since medical school
- 29 years
- Graduated 1997
Offices
2 locations · Peninsula Orthopedic Associates Inc · 18 clinicians in this group
Hospitals listed: Marinhealth Medical Center · Novato Community Hospital. That is not proof they admit you there this week.
Plans that list them
12 plans · 2 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Celis’s office to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
12 of 12 plans
| Alignment Health BreathEasy (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Clarity (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Harmony (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes CalPlus (HMO C-SNP) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health Heart & Diabetes Care (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Heart & Diabetes Choice (HMO C-SNP) | Alignment Health Plan | Listed | Sep 28, 2026 |
| Alignment Health Honor+ Plan (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Alignment Health My Choice CalCare (HMO) | Alignment Health Plan | Listed | Oct 3, 2026 |
| Imperial Courage Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Dynamic Plan (HMO) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
| Imperial Senior Value (HMO C-SNP) | Imperial Health Plan of California, Inc. | Listed | Sep 1, 2026 |
California Medical Board record
Licence C131803 · Current
Licensed to practise in California · since 2014 · expires 2027-11-30 · Pontifical Javerian University Faculty of Medicine.
No disciplinary actions, convictions, malpractice judgments or citations in this record.
Surgery centers they own
- North Bay Regional Surgery Center, LLC dba North Bay Regional Surgery CenterAmbulatory Surgery Center · Novato, CA1.2% owner since 2023 · accredited by AAAHCAccreditation Renewed5 inspections, 2 with deficiencies · last 2024-12-03
State licence records
1 licence
- Florida ME96425Medical Doctor · since 2006 · expires 2026-01-31ActiveNo board action on this licenceCheck it with the state
We check Colorado, Delaware, Florida, Illinois, Maryland, New Jersey, New York, Tennessee, Texas, Virginia, Washington, plus California above. A state that is not in this list has not been checked, which is not the same as clear.
School, training and certification
3 placements
What this clinician told their state board, medical school and everything before it. Only some states publish this, so nothing here means the state does not say, not that there was no training or certification.
Specialty certification
- Anesthesiology
- Pain Management
Education
- Pontificia Universidad Javeriana · MD1997Medical school
Residency and fellowship
- Brigham and Womens Hospital, PAIN MANAGEMENTBoston, MA · 2005–2006
- Brigham and Womens Hospital, ANESTHESIOLOGYBoston, MA · 2002–2005
- Beth Israel Medical Center, SURGERYNew York, NY · 2001–2002
What else the board holds
Hospitals they may admit to
Where the clinician told their state board they may admit and treat patients.
- Out of State · CA
Also licensed in
States the clinician told their board they are also licensed in. Only the states we check are verified.
California · Massachusetts
Hospitals they work in
2 hospitals
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Marinhealth Medical CenterGreenbrae, CAAcute Care Hospital · Government - Hospital District or Authority · Has an emergency department · Birthing-friendlyPart of MarinHealthPatients rate it 3 of 5 · 76% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.66 (3.59 to 7.73) · 1,505 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.177, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025
- Novato Community HospitalNovato, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Sutter Health, which runs 27 hospitals in 2 statesPatients rate it 4 of 5 · 84% would definitely recommend itOverall rating: 5 of 5 starsBetter than the national rate — Clostridium Difficile (C.Diff): 0, Oct 2024 – Sep 2025
See every measure and the patient survey for Marinhealth Medical Center
Behind the star rating — Deaths: 2 better, 6 the same, 0 worse of 8 measures. Safety: 1 better, 6 the same, 0 worse of 7 measures. Readmissions: 3 better, 8 the same, 0 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.66 (3.59 to 7.73) · 1,505 cases | Worse | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.177 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 0.85 (0 to 1.83) · 1,056 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 1.04 (0.72 to 1.36) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 167.34 (112.58 to 222.09) · 57 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.9 · 47 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 8.5 · 119 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.6 · 257 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 9.5 · 428 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 11.4 · 477 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 9.3 · 197 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.1 · 2,827 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.18 (0 to 0.38) · 6,990 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.21 (0.02 to 0.41) · 6,838 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.41 (0 to 3) · 664 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.86 (1.4 to 4.33) · 1,436 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 10.38 (3.68 to 17.08) · 705 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.38 (0.72 to 8.04) · 672 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.66 (0.18 to 3.15) · 300 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.56 (0 to 1.25) · 5,550 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.4 · 76 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.396 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0 | No different | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 13.1 · 275 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 22 · 427 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | -20.3 · 289 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | 3.3 · 494 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | -4.9 · 499 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 17.9 · 435 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.5 (3.6 to 8.4) · 93 cases | No different | Jan 2024 – Dec 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 11.2 (7.8 to 16) · 93 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 6.6 · 84 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 10.5 · 53 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.3 · 111 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 13 (10.3 to 16.5) · 2,119 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1.1 (0.8 to 1.4) · 670 cases | No different | Jan 2024 – Dec 2024 |
What patients said (1,233 patients answered, 19% of those asked)
| Cleanliness | 3 |
| Nurse communication | 3 |
| Doctor communication | 3 |
| Communication about medicines | 2 |
| Discharge information | 3 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 4 |
| Room was "always" clean | 68% |
| Nurses "always" communicated well | 73% |
| Doctors "always" communicated well | 74% |
| Staff "always" explained | 56% |
| Yes, staff "did" give patients this information | 85% |
| Yes, staff "did" give patients information about help after discharge | 85% |
| Doctors "always" explained things so they could understand | 71% |
| Doctors "always" listened carefully | 72% |
| Doctors "always" treated them with courtesy and respect | 80% |
| Patients who gave a rating of "9" or "10" (high) | 72% |
| Staff "always" explained new medications | 70% |
| Nurses "always" explained things so they could understand | 68% |
| Nurses "always" listened carefully | 68% |
| Nurses "always" treated them with courtesy and respect | 82% |
| "Always" quiet at night | 48% |
| "YES", patients would definitely recommend the hospital | 76% |
| Staff "always" explained possible side effects | 43% |
| Yes, staff "did" give patients information about possible symptoms | 85% |
See every measure and the patient survey for Novato Community Hospital
Behind the star rating — Deaths: 0 better, 5 the same, 0 worse of 5 measures. Safety: 0 better, 3 the same, 0 worse of 3 measures. Readmissions: 0 better, 7 the same, 0 worse of 7 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Clostridium Difficile (C.Diff)Infections | 0 | Better | Oct 2024 – Sep 2025 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1 (0 to 2.06) · 213 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.85 (0.4 to 1.3) | No different | Jul 2022 – Jun 2024 |
| Death rate for COPD patientsComplications and deaths | 8.2 · 25 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 10 · 111 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 16.1 · 140 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 11.3 · 42 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 3.8 · 627 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.2 (0 to 0.43) · 1,872 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.25 (0.04 to 0.46) · 1,796 cases | No different | Jul 2022 – Jun 2024 |
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 2.92 (0.5 to 5.33) · 505 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 1.64 (0 to 3.36) · 317 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.2 (0.51 to 3.88) · 495 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative respiratory failure rateComplications and deaths | 7.93 (0 to 17.29) · 323 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 4.88 (0.69 to 9.07) · 311 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.75 (0.22 to 3.27) · 96 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.41 (0 to 1.49) · 1,320 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.2 · 143 cases | None | Apr 2023 – Mar 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 19.6 · 108 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -31.9 · 121 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 1.1 · 150 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.6 · 143 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.4 · 118 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 27 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.5 (9.5 to 16.5) · 930 cases | No different | Jan 2022 – Dec 2024 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 1 (0.7 to 1.3) · 184 cases | No different | Jan 2024 – Dec 2024 |
What patients said (334 patients answered, 30% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 3 |
| Recommend hospital | 5 |
| Room was "always" clean | 78% |
| Nurses "always" communicated well | 81% |
| Doctors "always" communicated well | 83% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 78% |
| Doctors "always" listened carefully | 84% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 82% |
| Staff "always" explained new medications | 77% |
| Nurses "always" explained things so they could understand | 76% |
| Nurses "always" listened carefully | 82% |
| Nurses "always" treated them with courtesy and respect | 86% |
| "Always" quiet at night | 54% |
| "YES", patients would definitely recommend the hospital | 84% |
| Staff "always" explained possible side effects | 49% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$168,107
Medicare paid this office $168,107 for 189 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Return visit (30+ min) | 134 | $73,776 | $112 |
| Short return visit (20+ min) | 122 | $37,243 | $83 |
| Evaluation of neuropsychological test, first hour | 72 | $13,142 | $117 |
| New patient visit (45+ min) | 49 | $6,785 | $138 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, single facet joint | 21 | $5,539 | $252 |
See all 18 services
| Return visit (30+ min) | 134 | $73,776 | $112 |
| Short return visit (20+ min) | 122 | $37,243 | $83 |
| Evaluation of neuropsychological test, first hour | 72 | $13,142 | $117 |
| New patient visit (45+ min) | 49 | $6,785 | $138 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, single facet joint | 21 | $5,539 | $252 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 31 | $5,012 | $129 |
| Administration of psychological or neuropsychological test by technician, first 30 minutes | 79 | $4,701 | $37 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 14 | $2,676 | $111 |
| Injection of lower or sacral spine facet joint using imaging guidance, single level | 11 | $2,034 | $120 |
| Ultrasonic guidance for needle placement | 12 | $1,863 | $56 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, each additional facet joint | 20 | $1,417 | $64 |
| Injection of anesthetic or steroid into joint between lower spine and hip bone using imaging guidance | 11 | $1,123 | $94 |
| Injection of lower or sacral spine facet joint using imaging guidance, second level | 11 | $1,096 | $64 |
| Injection of substance into middle or upper spine canal using imaging guidance | 11 | $1,061 | $88 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, each additional level | 12 | $656 | $47 |
| Assessment of emotional or behavioral problems | 53 | $515 | $4 |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 17 | $23 | None |
| Injection, bupivicaine, not otherwise specified, 0.5 mg | 22 | $0 | None |
Procedures year by year
| Procedure | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 51 | 30 | 29 | 28 | 23 | 39 |
| Injection of anesthetic or steroid into joint between lower spine and hip bone using imaging guidance | 21 | 28 | 21 | 24 | 24 | 12 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, each additional facet joint | 32 | 17 | 25 | – | 15 | 22 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, single facet joint | 21 | 17 | 18 | 14 | 18 | 22 |
| Injection of lower or sacral spine facet joint using imaging guidance, single level | 20 | 25 | 16 | 17 | – | 17 |
| Injection of lower or sacral spine facet joint using imaging guidance, second level | 19 | 20 | 15 | – | – | 17 |
Times billed to Original Medicare each year. A blank year means fewer than 11 people had it, or none: Medicare does not publish smaller counts. Medicare Advantage patients are not included.
Who their Medicare patients are
189 Original Medicare patients in 2024. Average age 75 · Under 65 8% · 85 and older 12% · Women 62% · Also on Medicaid 6% · Health risk score 1.21. At or below the middle of the specialty; the typical pain management clinician is at 1.38.
Conditions among them: High blood pressure 68% · Depression 35% · Coronary heart disease 28% · Chronic kidney disease 22% · Diabetes 21% · Atrial fibrillation 15% · Heart failure 13% · Cancer 12% · Stroke 12% · COPD 11%.
The office billed $536,392, Medicare allowed $222,587 and paid $168,107; for 1,918 services of 43 kinds; $381 of it was for drugs given in the office and $167,726 for care.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 189 | 1,918 | 75 | 1.21 | $536,392 | $168,107 |
| 2023 | 176 | 1,640 | 74 | 1.18 | $457,883 | $128,544 |
| 2022 | 198 | 1,815 | 72 | 1.13 | $525,200 | $141,318 |
| 2021 | 188 | 1,773 | 71 | 1.15 | $509,441 | $141,553 |
| 2020 | 179 | 2,119 | 71 | 1.08 | $489,448 | $115,869 |
| 2019 | 201 | 1,739 | 72 | 1.26 | $519,170 | $125,073 |
| 2018 | 237 | 2,412 | 70 | 1.40 | $704,433 | $143,262 |
| 2017 | 171 | 3,995 | 70 | 1.27 | $674,435 | $140,761 |
| 2016 | 309 | 3,860 | 69 | 1.53 | $666,144 | $175,720 |
| 2015 | 384 | 3,293 | 68 | 1.43 | $583,472 | $113,910 |
| 2014 | 185 | 194 | 71 | 1.12 | $505,925 | $35,062 |
| 2013 | 230 | 242 | 71 | 1.49 | $572,050 | $41,273 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 10 services
| Return visit (30+ min) | 128 | $69,182 | $109 |
| Short return visit (20+ min) | 96 | $23,873 | $80 |
| New patient visit (45+ min) | 37 | $5,674 | $153 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, single facet joint | 17 | $4,155 | $231 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 18 | $2,844 | $124 |
| Injection of anesthetic or steroid into joint between lower spine and hip bone using imaging guidance | 20 | $2,204 | $92 |
| Assessment of emotional or behavioral problems | 73 | $1,552 | $5 |
| Ultrasonic guidance for needle placement | 15 | $1,143 | $57 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, each additional facet joint | 14 | $880 | $59 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 31 | $533 | $10 |
2022: 12 services
| Return visit (30+ min) | 136 | $79,888 | $109 |
| Short return visit (20+ min) | 109 | $22,519 | $73 |
| New patient visit (45+ min) | 38 | $5,691 | $150 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 21 | $3,479 | $124 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, single facet joint | 13 | $3,393 | $242 |
| Injection of upper or middle spine facet joint using imaging guidance, single level | 16 | $3,007 | $137 |
| Injection of anesthetic or steroid into joint between lower spine and hip bone using imaging guidance | 21 | $2,159 | $90 |
| Injection of lower or sacral spine facet joint using imaging guidance, single level | 12 | $2,005 | $118 |
| Assessment of emotional or behavioral problems | 87 | $1,729 | $4 |
| Injection of upper or middle spine facet joint using imaging guidance, second level | 16 | $1,660 | $75 |
| Ultrasonic guidance for needle placement | 14 | $852 | $53 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 35 | $617 | $11 |
2021: 14 services
| Return visit (30+ min) | 119 | $68,196 | $112 |
| Short return visit (20+ min) | 107 | $29,565 | $79 |
| New patient visit (45+ min) | 44 | $6,566 | $149 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, single facet joint | 16 | $5,100 | $283 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 21 | $3,641 | $126 |
| Injection of upper or middle spine facet joint using imaging guidance, single level | 20 | $2,909 | $116 |
| Injection of lower or sacral spine facet joint using imaging guidance, single level | 12 | $1,915 | $120 |
| Injection of anesthetic or steroid into joint between lower spine and hip bone using imaging guidance | 17 | $1,830 | $87 |
| Assessment of emotional or behavioral problems | 84 | $1,648 | $5 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, each additional facet joint | 15 | $1,419 | $57 |
| Injection of upper or middle spine facet joint using imaging guidance, second level | 14 | $1,184 | $62 |
| Injection of lower or sacral spine facet joint using imaging guidance, second level | 11 | $997 | $66 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 29 | $696 | $11 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, each additional level | 11 | $656 | $50 |
2020: 13 services
| Return visit (30+ min) | 104 | $52,011 | $89 |
| Short return visit (20+ min) | 95 | $22,550 | $69 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, single facet joint | 15 | $4,842 | $285 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 27 | $3,551 | $118 |
| New patient visit (45+ min) | 24 | $3,474 | $145 |
| Injection of lower or sacral spine facet joint using imaging guidance, single level | 19 | $2,756 | $110 |
| Injection of upper or middle spine facet joint using imaging guidance, single level | 13 | $2,554 | $134 |
| Injection of anesthetic or steroid into joint between lower spine and hip bone using imaging guidance | 24 | $2,318 | $83 |
| Extended patient service without direct patient contact, first hour | 24 | $2,265 | $94 |
| Injection of lower or sacral spine facet joint using imaging guidance, second level | 15 | $1,283 | $64 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, each additional facet joint | 14 | $1,267 | $75 |
| Assessment of emotional or behavioral problems | 78 | $1,241 | $4 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 28 | $513 | $11 |
2019: 15 services
| Return visit (30+ min) | 109 | $69,440 | $95 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 44 | $6,157 | $121 |
| New patient visit (45+ min) | 44 | $6,115 | $139 |
| Short return visit (20+ min) | 46 | $6,038 | $66 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, single facet joint | 16 | $4,762 | $227 |
| Extended patient service without direct patient contact, first hour | 34 | $3,297 | $97 |
| Injection of lower or sacral spine facet joint using imaging guidance, single level | 14 | $2,142 | $107 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, each additional facet joint | 16 | $1,952 | $61 |
| Injection of anesthetic or steroid into joint between lower spine and hip bone using imaging guidance | 17 | $1,832 | $87 |
| Ultrasonic guidance for needle placement | 17 | $1,486 | $53 |
| Assessment of emotional or behavioral problems | 77 | $1,356 | $5 |
| Injection of lower or sacral spine facet joint using imaging guidance, second level | 13 | $1,137 | $60 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, each additional level | 18 | $1,004 | $50 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 30 | $550 | $11 |
| Administration of psychological or neuropsychological test by single standardized instrument via electronic platform with automated result | 31 | $61 | $2 |
2018: 22 services
| Return visit (30+ min) | 143 | $62,808 | $89 |
| Testing for presence of drug, by chemistry analyzers | 102 | $15,495 | $70 |
| Short return visit (20+ min) | 97 | $13,751 | $59 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 34 | $5,681 | $116 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, single facet joint | 15 | $4,774 | $239 |
| Injection of lower or sacral spine facet joint using imaging guidance, single level | 20 | $2,794 | $107 |
| Extended patient service without direct patient contact, first hour | 29 | $2,769 | $95 |
| New patient visit (45+ min) | 19 | $2,615 | $138 |
| Long return visit (40+ min) | 21 | $2,607 | $119 |
| Injection of drug or substance under skin or into muscle | 32 | $2,204 | $18 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 13 | $1,960 | $75 |
| Assessment of emotional or behavioral problems | 88 | $1,953 | $6 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, each additional facet joint | 14 | $1,884 | $59 |
| Injection of anesthetic or steroid into joint between lower spine and hip bone using imaging guidance | 19 | $1,834 | $76 |
| Ultrasonic guidance for needle placement | 15 | $1,524 | $56 |
| Injection of upper or middle spine facet joint using imaging guidance, single level | 11 | $1,308 | $119 |
| Injection of lower or sacral spine facet joint using imaging guidance, second level | 12 | $1,115 | $62 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, each additional level | 15 | $1,046 | $48 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 34 | $862 | $11 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 29 | $91 | None |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 34 | $65 | None |
| Injection, ketorolac tromethamine, per 15 mg | 27 | $51 | None |
2017: 19 services
| Return visit (30+ min) | 131 | $56,391 | $92 |
| Testing for presence of drug, by chemistry analyzers | 94 | $15,486 | $78 |
| Short return visit (20+ min) | 70 | $13,236 | $65 |
| Injection of drug or substance under skin or into muscle | 49 | $7,639 | $24 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, single facet joint | 13 | $5,398 | $245 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 22 | $4,951 | $124 |
| New patient visit (45+ min) | 29 | $3,929 | $135 |
| New patient visit (60+ min) | 14 | $2,425 | $173 |
| Ultrasonic guidance for needle placement | 25 | $2,193 | $56 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 13 | $2,147 | $86 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, each additional facet joint | 12 | $2,021 | $63 |
| Extended patient service without direct patient contact, first hour | 14 | $1,559 | $97 |
| Psychological testing with interpretation and report by computer | 50 | $1,365 | $22 |
| Injection of trigger points, 3 or more muscles | 11 | $966 | $57 |
| Use of a drug to induce depression of consciousness by physician performing a procedure (5 years or older), initial 15 minutes | 36 | $899 | $11 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 47 | $396 | None |
| Unclassified drugs | 28 | $230 | None |
| Injection, ketorolac tromethamine, per 15 mg | 47 | $171 | None |
| Injection, triamcinolone acetonide, not otherwise specified, 10 mg | 30 | $61 | None |
2016: 25 services
| Return visit (30+ min) | 201 | $64,976 | $94 |
| Drug tests(s), presumptive, any number of drug classes; any number of devices or procedures by instrumented chemistry analyzers utilizing immunoassay, enzyme assay, TOF, MALDI, LDTD, DESI, DART, GHPC, GC mass spectrometry), includes sample validation when | 145 | $21,604 | $77 |
| Short return visit (20+ min) | 108 | $13,308 | $62 |
| Injection of drug or substance under skin or into muscle | 114 | $12,654 | $24 |
| New patient visit (45+ min) | 46 | $6,184 | $134 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, single facet joint | 15 | $4,994 | $238 |
| New patient visit (60+ min) | 26 | $4,523 | $174 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 21 | $3,476 | $124 |
| Ultrasonic guidance for needle placement | 34 | $2,885 | $57 |
| Moderate sedation services by physician also performing a procedure, patient 5 years of age or older, first 30 minutes | 41 | $2,873 | $36 |
| Long return visit (40+ min) | 15 | $2,735 | $130 |
| Psychological testing with interpretation and report by computer | 75 | $2,518 | $24 |
| Injection of lower or sacral spine facet joint using imaging guidance, single level | 16 | $2,475 | $118 |
| Injection of anesthetic or steroid into joint between lower spine and hip bone using imaging guidance | 17 | $2,055 | $103 |
| Destruction of lower or sacral spinal facet joint nerves using imaging guidance, each additional facet joint | 13 | $1,595 | $64 |
| Injection of trigger points, 3 or more muscles | 21 | $1,402 | $58 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 11 | $1,358 | $75 |
| Injection of lower or sacral spine facet joint using imaging guidance, second level | 13 | $1,125 | $66 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 110 | $863 | None |
| Injection of trigger points, 1-2 muscles | 11 | $788 | $49 |
| Injection, pyridoxine hcl, 100 mg | 61 | $730 | None |
| Administration of influenza virus vaccine | 13 | $392 | $30 |
| Injection, triamcinolone hexacetonide, per 5 mg | 39 | $290 | None |
| Injection, ketorolac tromethamine, per 15 mg | 110 | $289 | None |
| Injection, thiamine hcl, 100 mg | 61 | $238 | None |
2015: 24 services
| Return visit (30+ min) | 171 | $31,534 | $96 |
| Drug screen, qualitative; multiple drug classes by high complexity test method (e.g., immunoassay, enzyme assay), per patient encounter | 98 | $13,383 | $97 |
| New patient visit (45+ min) | 75 | $10,854 | $145 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, single level | 55 | $8,659 | $124 |
| Short return visit (20+ min) | 87 | $8,495 | $65 |
| Injection of drug or substance under skin or into muscle | 80 | $5,545 | $24 |
| New patient visit (60+ min) | 19 | $3,427 | $180 |
| Injection of anesthetic or steroid into joint between lower spine and hip bone using imaging guidance | 33 | $3,227 | $92 |
| Injection of lower or sacral spine facet joint using imaging guidance, single level | 16 | $2,338 | $111 |
| Psychological testing with interpretation and report by computer | 68 | $2,094 | $24 |
| Aspiration and/or injection of fluid large joint using ultrasound guidance | 15 | $1,786 | $85 |
| Ultrasonic guidance for needle placement | 19 | $1,445 | $56 |
| Injection of trigger points, 3 or more muscles | 19 | $1,322 | $57 |
| Injection of anesthetic and/or steroid drug into sacral spine nerve root using imaging guidance, each additional level | 21 | $1,240 | $50 |
| Injections of substances into upper or middle spine | 12 | $1,156 | $96 |
| Injection of lower or sacral spine facet joint using imaging guidance, second level | 13 | $1,040 | $61 |
| Moderate sedation services by physician also performing a procedure, patient 5 years of age or older, first 30 minutes | 17 | $930 | $36 |
| Injection, pyridoxine hcl, 100 mg | 72 | $678 | None |
| Injection, triamcinolone hexacetonide, per 5 mg | 29 | $572 | None |
| Office for the evaluation and management of established patient that may not require presence of healthcare professional | 25 | $503 | $19 |
| Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg | 79 | $293 | None |
| Injection, thiamine hcl, 100 mg | 71 | $289 | None |
| Unclassified drugs | 31 | $147 | None |
| Injection, ketorolac tromethamine, per 15 mg | 71 | $103 | None |
2014: 3 services
| Anesthesia for procedure on gastrointestinal tract using an endoscope | 59 | $8,323 | $139 |
| Anesthesia for procedure on lower intestine using an endoscope | 59 | $7,611 | $129 |
| Anesthesia for procedure for total knee joint replacement | 12 | $4,761 | $366 |
2013: 3 services
| Anesthesia for procedure on lower intestine using an endoscope | 80 | $11,015 | $138 |
| Anesthesia for procedure on gastrointestinal tract using an endoscope | 63 | $8,649 | $135 |
| Anesthesia for other closed procedure on chest | 11 | $2,068 | $188 |
Drugs they prescribed that Part D paid
$98,593
Pharmacies billed $98,593 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 64% of their Part D prescriptions (1,155 of 1,817) in 2024. Above the middle of the specialty; the typical pain management clinician is at 44%. Long-acting opioids: 21% of their opioid prescriptions.
1,739 generic and 78 brand-name prescriptions · $98,593 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Hydrocodone-Acetaminophen | None | 520 | $12,873 | $25 |
| Buprenorphine | None | 52 | $9,715 | $187 |
| Aimovig | Migraine | 13 | $9,273 | $713 |
| Butrans | None | 13 | $6,677 | $514 |
| Buprenorphine-Naloxone | None | 44 | $4,011 | $91 |
See all 27 drugs
| Hydrocodone-Acetaminophen | None | 520 | $12,873 | $25 |
| Buprenorphine | None | 52 | $9,715 | $187 |
| Aimovig | Migraine | 13 | $9,273 | $713 |
| Butrans | None | 13 | $6,677 | $514 |
| Buprenorphine-Naloxone | None | 44 | $4,011 | $91 |
| Fentanyl | None | 37 | $3,461 | $94 |
| Oxycodone-Acetaminophen | None | 84 | $2,396 | $29 |
| Gabapentin | None | 131 | $2,312 | $18 |
| Oxycodone | None | 154 | $2,280 | $15 |
| Morphine Sulfate Er | None | 68 | $1,796 | $26 |
| Buprenorphine | None | 61 | $1,561 | $26 |
| Pregabalin | None | 67 | $1,447 | $22 |
| Baclofen | None | 37 | $979 | $26 |
| Celecoxib | None | 25 | $848 | $34 |
| Methadone | None | 64 | $830 | $13 |
| Morphine Sulfate | None | 15 | $671 | $45 |
| Hydromorphone | None | 46 | $502 | $11 |
| Cyclobenzaprine | None | 39 | $470 | $12 |
| Tramadol | None | 65 | $364 | $6 |
| Nortriptyline | None | 11 | $335 | $30 |
| Duloxetine | None | 24 | $334 | $14 |
| Acetaminophen-Codeine | None | 23 | $285 | $12 |
| Ibuprofen | None | 18 | $204 | $11 |
| Trazodone | None | 11 | $128 | $12 |
| Meloxicam | None | 69 | $125 | $2 |
| Naproxen | None | 12 | $110 | $9 |
| Methocarbamol | None | 19 | $69 | $4 |
Year by year
| 2024 | 1,817 | 169 | 64% (1,155) | 4% | $98,593 |
| 2023 | 1,708 | 158 | 60% (1,032) | 4% | $111,652 |
| 2022 | 1,622 | 147 | 62% (997) | 7% | $103,226 |
| 2021 | 1,562 | 130 | 67% (1,040) | 11% | $108,697 |
| 2020 | 1,662 | 108 | 65% (1,076) | 8% | $87,224 |
| 2019 | 1,555 | 111 | 65% (1,017) | 15% | $115,833 |
| 2018 | 1,582 | 118 | 66% (1,039) | 18% | $137,221 |
| 2017 | 1,502 | 124 | 63% (952) | 20% | $131,085 |
| 2016 | 1,606 | 207 | 62% (989) | 21% | $156,975 |
| 2015 | 713 | 183 | 70% (498) | 17% | $85,743 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 29 drugs
| Buprenorphine | None | 69 | $22,845 | $331 |
| Hydrocodone-Acetaminophen | None | 407 | $11,954 | $29 |
| Butrans | None | 13 | $10,860 | $835 |
| Lidocaine | None | 17 | $9,995 | $588 |
| Aimovig | Migraine | 11 | $8,411 | $765 |
| Fentanyl | None | 38 | $4,151 | $109 |
| Pregabalin | None | 71 | $3,915 | $55 |
| Gabapentin | None | 126 | $3,481 | $28 |
| Oxycodone | None | 167 | $3,297 | $20 |
| Buprenorphine-Naloxone | None | 49 | $3,061 | $62 |
| Buprenorphine | None | 49 | $2,838 | $58 |
| Morphine Sulfate Er | None | 83 | $2,246 | $27 |
| Oxycodone-Acetaminophen | None | 70 | $1,264 | $18 |
| Baclofen | None | 58 | $1,217 | $21 |
| Naloxone | None | 14 | $1,065 | $76 |
| Celecoxib | None | 34 | $1,041 | $31 |
| Methadone | None | 59 | $835 | $14 |
| Morphine Sulfate | None | 19 | $784 | $41 |
| Nabumetone | None | 20 | $697 | $35 |
| Duloxetine | None | 17 | $526 | $31 |
| Nortriptyline | None | 25 | $489 | $20 |
| Hydromorphone | None | 44 | $426 | $10 |
| Acetaminophen-Codeine | None | 21 | $363 | $17 |
| Trazodone | None | 13 | $336 | $26 |
| Ibuprofen | None | 18 | $261 | $15 |
| Naproxen | None | 14 | $238 | $17 |
| Tramadol | None | 33 | $223 | $7 |
| Cyclobenzaprine | None | 23 | $190 | $8 |
| Meloxicam | None | 39 | $75 | $2 |
2022: 26 drugs
| Buprenorphine | None | 49 | $15,180 | $310 |
| Hydrocodone-Acetaminophen | None | 364 | $11,152 | $31 |
| Aimovig | Migraine | 11 | $8,507 | $773 |
| Butrans | None | 13 | $7,904 | $608 |
| Oxycontin | None | 15 | $6,680 | $445 |
| Buprenorphine-Naloxone | None | 72 | $6,026 | $84 |
| Fentanyl | None | 36 | $4,335 | $120 |
| Buprenorphine | None | 56 | $3,737 | $67 |
| Gabapentin | None | 143 | $3,545 | $25 |
| Pregabalin | None | 43 | $3,489 | $81 |
| Oxycodone | None | 144 | $3,282 | $23 |
| Morphine Sulfate Er | None | 107 | $2,944 | $28 |
| Baclofen | None | 52 | $1,650 | $32 |
| Acetaminophen-Codeine | None | 39 | $1,038 | $27 |
| Methadone | None | 65 | $951 | $15 |
| Morphine Sulfate | None | 28 | $864 | $31 |
| Oxycodone-Acetaminophen | None | 44 | $759 | $17 |
| Celecoxib | None | 17 | $613 | $36 |
| Duloxetine | None | 13 | $600 | $46 |
| Hydromorphone | None | 51 | $492 | $10 |
| Trazodone | None | 17 | $471 | $28 |
| Nortriptyline | None | 29 | $430 | $15 |
| Tramadol | None | 37 | $381 | $10 |
| Nabumetone | None | 17 | $333 | $20 |
| Cyclobenzaprine | None | 18 | $264 | $15 |
| Meloxicam | None | 39 | $194 | $5 |
2021: 28 drugs
| Nucynta Er | None | 19 | $14,179 | $746 |
| Hydrocodone-Acetaminophen | None | 389 | $12,593 | $32 |
| Buprenorphine-Naloxone | None | 67 | $8,551 | $128 |
| Xtampza Er | None | 16 | $8,056 | $503 |
| Aimovig | Migraine | 12 | $7,427 | $619 |
| Oxycontin | None | 25 | $6,945 | $278 |
| Butrans | None | 12 | $6,165 | $514 |
| Buprenorphine | None | 16 | $4,402 | $275 |
| Oxycodone | None | 167 | $4,137 | $25 |
| Pregabalin | None | 51 | $3,196 | $63 |
| Suboxone | None | 15 | $2,884 | $192 |
| Fentanyl | None | 33 | $2,707 | $82 |
| Morphine Sulfate Er | None | 110 | $2,675 | $24 |
| Gabapentin | None | 100 | $2,607 | $26 |
| Oxycodone-Acetaminophen | None | 54 | $1,118 | $21 |
| Methadone | None | 77 | $958 | $12 |
| Buprenorphine | None | 21 | $809 | $39 |
| Morphine Sulfate | None | 17 | $755 | $44 |
| Trazodone | None | 27 | $577 | $21 |
| Nortriptyline | None | 31 | $549 | $18 |
| Hydromorphone | None | 59 | $487 | $8 |
| Baclofen | None | 26 | $459 | $18 |
| Acetaminophen-Codeine | None | 17 | $388 | $23 |
| Duloxetine | None | 11 | $340 | $31 |
| Meloxicam | None | 34 | $177 | $5 |
| Tizanidine | None | 12 | $163 | $14 |
| Cyclobenzaprine | None | 20 | $134 | $7 |
| Tramadol | None | 21 | $129 | $6 |
2020: 24 drugs
| Oxycontin | None | 40 | $10,447 | $261 |
| Hydrocodone-Acetaminophen | None | 405 | $10,061 | $25 |
| Buprenorphine-Naloxone | None | 38 | $7,602 | $200 |
| Suboxone | None | 28 | $7,506 | $268 |
| Aimovig | Migraine | 12 | $7,063 | $589 |
| Butrans | None | 13 | $6,217 | $478 |
| Oxycodone | None | 216 | $5,524 | $26 |
| Pregabalin | None | 69 | $3,348 | $49 |
| Morphine Sulfate Er | None | 108 | $2,578 | $24 |
| Tramadol Hcl Er | None | 12 | $2,136 | $178 |
| Gabapentin | None | 86 | $1,680 | $20 |
| Oxycodone-Acetaminophen | None | 68 | $1,474 | $22 |
| Fentanyl | None | 29 | $1,474 | $51 |
| Methadone | None | 96 | $1,113 | $12 |
| Duloxetine | None | 24 | $778 | $32 |
| Nortriptyline | None | 64 | $776 | $12 |
| Baclofen | None | 37 | $577 | $16 |
| Trazodone | None | 30 | $537 | $18 |
| Diclofenac | None | 22 | $513 | $23 |
| Hydromorphone | None | 41 | $397 | $10 |
| Cyclobenzaprine | None | 36 | $264 | $7 |
| Meloxicam | None | 37 | $263 | $7 |
| Ibuprofen | None | 12 | $103 | $9 |
| Tramadol | None | 16 | $47 | $3 |
2019: 31 drugs
| Lyrica | None | 52 | $35,953 | $691 |
| Hydrocodone-Acetaminophen | None | 363 | $11,090 | $31 |
| Suboxone | None | 33 | $9,249 | $280 |
| Aimovig | Migraine | 13 | $7,343 | $565 |
| Butrans | None | 12 | $5,338 | $445 |
| Nucynta Er | None | 12 | $4,924 | $410 |
| Nucynta | None | 11 | $4,192 | $381 |
| Oxycontin | None | 16 | $3,960 | $248 |
| Morphine Sulfate Er | None | 108 | $3,849 | $36 |
| Oxycodone | None | 159 | $3,808 | $24 |
| Buprenorphine | None | 17 | $3,755 | $221 |
| Buprenorphine-Naloxone | None | 14 | $3,505 | $250 |
| Oxycodone-Acetaminophen | None | 97 | $2,571 | $27 |
| Tramadol Hcl Er | None | 17 | $1,805 | $106 |
| Gabapentin | None | 106 | $1,622 | $15 |
| Fentanyl | None | 26 | $1,187 | $46 |
| Methadone | None | 71 | $1,028 | $14 |
| Pregabalin | None | 21 | $1,025 | $49 |
| Morphine Sulfate | None | 21 | $848 | $40 |
| Duloxetine | None | 18 | $780 | $43 |
| Nortriptyline | None | 59 | $619 | $10 |
| Diclofenac | None | 21 | $604 | $29 |
| Cyclobenzaprine | None | 21 | $358 | $17 |
| Hydromorphone | None | 28 | $269 | $10 |
| Meloxicam | None | 33 | $217 | $7 |
| Tramadol | None | 35 | $206 | $6 |
| Hydrocodone-Ibuprofen | None | 11 | $182 | $17 |
| Baclofen | None | 31 | $177 | $6 |
| Trazodone | None | 17 | $135 | $8 |
| Methocarbamol | None | 13 | $103 | $8 |
| Clonidine | None | 11 | $23 | $2 |
2018: 27 drugs
| Lyrica | 84 | $54,313 | $647 |
| Hydrocodone-Acetaminophen | 337 | $11,420 | $34 |
| Suboxone | 38 | $10,602 | $279 |
| Oxycontin | 47 | $10,332 | $220 |
| Kadian | 16 | $9,433 | $590 |
| Oxycodone | 194 | $5,761 | $30 |
| Butrans | 14 | $5,759 | $411 |
| Oxycodone-Acetaminophen | 123 | $3,641 | $30 |
| Fentanyl | 30 | $2,465 | $82 |
| Duloxetine | 34 | $2,420 | $71 |
| Morphine Sulfate Er | 50 | $2,181 | $44 |
| Methadone | 103 | $1,492 | $14 |
| Gabapentin | 97 | $1,409 | $15 |
| Diclofenac | 35 | $1,096 | $31 |
| Cyclobenzaprine | 31 | $1,031 | $33 |
| Voltaren | 16 | $881 | $55 |
| Hydrocodone-Ibuprofen | 12 | $860 | $72 |
| Nortriptyline | 58 | $553 | $10 |
| Morphine Sulfate | 20 | $460 | $23 |
| Celecoxib | 14 | $426 | $30 |
| Tramadol | 46 | $421 | $9 |
| Hydromorphone | 29 | $361 | $12 |
| Trazodone | 30 | $354 | $12 |
| Meloxicam | 12 | $189 | $16 |
| Baclofen | 18 | $131 | $7 |
| Tizanidine | 12 | $98 | $8 |
| Topiramate | 12 | $96 | $8 |
2017: 23 drugs
| Lyrica | 113 | $57,096 | $505 |
| Butrans | 31 | $13,519 | $436 |
| Suboxone | 32 | $9,174 | $287 |
| Oxycontin | 34 | $6,991 | $206 |
| Hydrocodone-Acetaminophen | 299 | $6,130 | $21 |
| Oxycodone | 186 | $5,311 | $29 |
| Fentanyl | 56 | $5,008 | $89 |
| Oxycodone-Acetaminophen | 116 | $4,562 | $39 |
| Morphine Sulfate Er | 67 | $3,604 | $54 |
| Duloxetine | 39 | $2,261 | $58 |
| Cyclobenzaprine | 34 | $1,666 | $49 |
| Methadone | 73 | $984 | $13 |
| Gabapentin | 92 | $894 | $10 |
| Diclofenac | 26 | $765 | $29 |
| Voltaren | 13 | $678 | $52 |
| Celecoxib | 13 | $587 | $45 |
| Buprenorphine | 17 | $465 | $27 |
| Trazodone | 30 | $368 | $12 |
| Hydromorphone | 29 | $342 | $12 |
| Meloxicam | 23 | $302 | $13 |
| Nortriptyline | 28 | $267 | $10 |
| Tramadol | 30 | $88 | $3 |
| Morphine Sulfate | 15 | $81 | $5 |
2016: 24 drugs
| Lyrica | 144 | $62,317 | $433 |
| Butrans | 51 | $20,756 | $407 |
| Hydrocodone-Acetaminophen | 314 | $10,107 | $32 |
| Oxycontin | 34 | $9,650 | $284 |
| Suboxone | 18 | $6,858 | $381 |
| Fentanyl | 75 | $6,574 | $88 |
| Oxycodone-Acetaminophen | 116 | $5,787 | $50 |
| Oxycodone | 173 | $5,138 | $30 |
| Duloxetine | 59 | $4,563 | $77 |
| Morphine Sulfate Er | 66 | $2,944 | $45 |
| Tramadol Hcl Er | 14 | $2,249 | $161 |
| Methadone | 87 | $2,002 | $23 |
| Gabapentin | 100 | $1,097 | $11 |
| Buprenorphine | 12 | $1,013 | $84 |
| Hydromorphone | 35 | $559 | $16 |
| Diclofenac | 17 | $482 | $28 |
| Trazodone | 23 | $330 | $14 |
| Baclofen | 27 | $287 | $11 |
| Tramadol | 39 | $274 | $7 |
| Nortriptyline | 30 | $267 | $9 |
| Morphine Sulfate | 12 | $214 | $18 |
| Cyclobenzaprine | 19 | $208 | $11 |
| Topiramate | 11 | $189 | $17 |
| Clonidine | 14 | $60 | $4 |
2015: 13 drugs
| Lyrica | 43 | $13,758 | $320 |
| Oxycontin | 17 | $10,027 | $590 |
| Oxycodone-Acetaminophen | 71 | $5,787 | $82 |
| Butrans | 15 | $4,540 | $303 |
| Fentanyl | 53 | $4,302 | $81 |
| Hydrocodone-Acetaminophen | 117 | $3,213 | $27 |
| Morphine Sulfate Er | 55 | $2,898 | $53 |
| Oxycodone | 86 | $2,604 | $30 |
| Methadone | 28 | $922 | $33 |
| Gabapentin | 39 | $592 | $15 |
| Hydromorphone | 20 | $258 | $13 |
| Cyclobenzaprine | 13 | $178 | $14 |
| Tramadol | 15 | $128 | $9 |
Money from drug and device companies
$115 in 2025
| 2025 | 3 | 4 | None | $115 |
| 2024 | 5 | 20 | None | $3,201 |
| 2023 | 2 | 5 | None | $118 |
| 2022 | 6 | 10 | None | $615 |
| 2021 | 8 | 15 | None | $565 |
| 2020 | 5 | 6 | None | $133 |
| 2019 | 7 | 12 | None | $329 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Vertex Pharmaceuticals | Journavx | $48 | 2 payments
|
| Bioventus | Stimrouter Implantable Kit | $45 | 1 payment
|
| Collegium Pharmaceutical | Belbuca | $21 | 1 payment
|
See all 4 published payments
| Vertex Pharmaceuticals | Meals · 2025-08-05 | Journavx | $15 |
| Bioventus | Meals · 2025-05-09 | Stimrouter Implantable Kit | $45 |
| Vertex Pharmaceuticals | Meals · 2025-04-29 | Journavx | $33 |
| Collegium Pharmaceutical | Meals · 2025-02-04 | Belbuca | $21 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $3,201
| Intuitive Surgical | Da Vinci Surgical System | $1,792 | 7 payments
|
| Si-Bone | Ifuse Implant System | $1,292 | 9 payments
|
| Biotronik Nro | Prospera | $62 | 1 payment
|
| Abbott Laboratories | Eterna | $40 | 2 payments
|
| Collegium Pharmaceutical | Belbuca | $16 | 1 payment
|
2023: $118
| Collegium Pharmaceutical | Belbuca | $62 | 3 payments
|
| Bioventus | Stimrouter Implantable Kit | $56 | 2 payments
|
2022: $615
| Relievant Medsystems | Intracept | $488 | 4 payments
|
| Collegium Pharmaceutical | Belbuca | $37 | 2 payments
|
| GRT US Holding | Qutenza | $25 | 1 payment
|
| Nalu Medical | Nalu Neurostimulation System | $24 | 1 payment
|
| Biohaven Pharmaceutical Holding Company | Nurtec Odt | $20 | 1 payment
|
| Bioventus | Stimrouter Implantable Kit | $20 | 1 payment
|
2021: $565
| Relievant Medsystems | Intracept | $252 | 1 payment
|
| Collegium Pharmaceutical | Xtampza | $96 | 4 payments
|
| Biohaven Pharmaceuticals | Nurtec Odt | $62 | 3 payments
|
| BioDelivery Sciences International | Belbuca | $43 | 2 payments
|
| Pfizer | Reyvow | $39 | 2 payments
|
| Boston Scientific | General - Pain Management | $33 | 1 payment
|
| Arbor Pharmaceuticals | Edarbi | $20 | 1 payment
|
| Bioventus | Durolane | $20 | 1 payment
|
2020: $133
| Abbott Laboratories | Neuromodulation Dspsbls and Accs | $45 | 1 payment
|
| Biodelivery Sciences International | Belbuca | $31 | 2 payments
|
| Collegium Pharmaceutical | Xtampza | $24 | 1 payment
|
| Nevro | Senza Spinal Cord Stimulation System | $20 | 1 payment
|
| Orthogenrx | Genvisc 850 | $13 | 1 payment
|
2019: $329
| Abbott Laboratories | Neuromodulation Dspsbls and Accs | $118 | 4 payments
|
| Nevro | Senza Spinal Cord Stimulation System | $85 | 2 payments
|
| Allergan | Botox | $44 | 2 payments
|
| Amgen | Aimovig | $33 | 1 payment
|
| Novartis Pharmaceuticals | Aimovig | $23 | 1 payment
|
| BioDelivery Sciences International | Bunavail 2.1 Mg 30-Count Box | $14 | 1 payment
|
| Bioventus | Gelsyn 3 | $12 | 1 payment
|
Professional record
- NPI
- 1851473268
- Licence
- CA C131803, FL ME96425California C131803: Current · expires 2027-11-30Florida ME96425: Active
- Gender
- Male
More record details
- Sole proprietor
- No
- Taxonomy
- Federal specialty code 207L00000X (207L00000X)
- Mailing address
- 1050 Northgate Dr Ste 460, San Rafael, CA, 94903
- NPI first listed
- 2006-10-19
- NPI last updated
- 2022-02-03
- NPI record certified
- 2022-02-03
This is when the NPI record was last certified, not a medical board exam.
Extra NPI addresses: 1850 Sullivan Ave Ste 330, Daly City, CA, 94015 · 455 Hickey Blvd Ste 310, Daly City, CA, 94015
This office lists an electronic records connection.